Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether a protein called TREM-1 can be used to differentiate viral and bacterial pneumonias in children who are on ventilator support. We propose that the level of TREM-1 will be significantly elevated in the lung fluid of children with bacterial pneumonia and viral with co-existing bacterial pneumonia than in children with pure viral pneumonia.


Clinical Trial Description

Most often, viruses are the cause of pneumonia in children. However, viral pneumonias are frequently associated with secondary bacterial pneumonia. It is important, though difficult, to differentiate patients who only have viral pneumonia from those who have viral pneumonia with secondary bacterial pneumonia. This will help physicians to prescribe antibiotics to only those with bacterial pneumonia and avoid antibiotic use in those with pure viral pneumonia, thus help to limit health-care cost and to decrease emergence of antibiotic resistance. In adult studies, TREM-1 has been shown to be specifically expressed in bacterial infections.

We propose that measuring TREM-1 in the bronchoalveolar lavage (BAL) fluid will help to differentiate these groups. Our hypothesis is that concentration of TREM-1 will be significantly elevated in the BAL fluid of children with bacterial pneumonia and viral with co-existing bacterial pneumonia than in children with pure viral pneumonia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00645619
Study type Observational
Source University of Texas Southwestern Medical Center
Contact
Status Withdrawn
Phase
Start date March 24, 2008
Completion date March 26, 2008

See also
  Status Clinical Trial Phase
Terminated NCT01570192 - Clinical Trials to Reduce the Risk of Antimicrobial Resistance Phase 2
Recruiting NCT04952337 - Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
Completed NCT02493764 - Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) Phase 3
Completed NCT02531438 - Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Phase 3
Completed NCT00079885 - Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Phase 3
Recruiting NCT05629741 - A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 Phase 1
Completed NCT05417997 - Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients Phase 3
Completed NCT00509106 - Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Phase 3
Completed NCT00080496 - Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Phase 3
Completed NCT03158727 - Cx611-0204 SEPCELL Study Phase 1/Phase 2
Completed NCT00621504 - Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia Phase 3
Completed NCT00124020 - Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Phase 3
Completed NCT00081575 - Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia Phase 3
Completed NCT00451386 - Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) Phase 2
Recruiting NCT03752320 - Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery
Active, not recruiting NCT04779242 - Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia Phase 3
Completed NCT00763620 - Assessment of the Diagnostic Capacity of the Mini-broncho Alveolar Lavage Performed Through a Suction Catheter N/A
Completed NCT00107952 - Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Phase 3
Terminated NCT03862040 - Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia Phase 1
Recruiting NCT05531149 - Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia Phase 3